INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $20,760 | +5363.2% | 300 | -94.3% | 0.00% | -90.0% |
| Q4 2023 | $380 | -67.1% | 5,300 | -76.1% | 0.01% | -79.2% |
| Q3 2023 | $1,156 | +25.1% | 22,200 | +52.1% | 0.05% | -4.0% |
| Q2 2023 | $924 | +38.7% | 14,600 | +18.7% | 0.05% | +22.0% |
| Q1 2023 | $666 | -99.1% | 12,300 | +925.0% | 0.04% | -62.4% |
| Q1 2022 | $73,000 | -66.0% | 1,200 | -70.7% | 0.11% | -73.7% |
| Q4 2021 | $215,000 | – | 4,100 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |